Yoshida H, Haraguchi C, Ogawa Y, Kawai N, Ohyama M, Higaki Y, Saitoh T, Imamura K
Hinyokika Kiyo. 1983 Nov;29(11):1419-26.
Twenty patients with benign prostatic hypertrophy were treated with an anti-androgenic agent, chlormadinone acetate ( Prostal ), 50 mg daily for 3 months. As a control, 20 patients with prostatic hypertrophy were treated with Eviprostat which was a non-hormonal remedy consisting of plant extracts 6 tablets daily for the same duration. Subjective symptoms of 14 patients (70%) in the Eviprostat group and 18 cases (90%) in the Prostal group were improved significantly. Although there were no significant changes in size or weight of the prostate after 3 months in the patients in the Eviprostat group as measured by transrectal ultrasonotomography, remarkable reduction in size and weight of the prostate was observed after 3 months in 11 patients (55%) in the Prostal group. Four cases complained of impotency during Prostal treatment, but no other side effects to the hepatic and/or renal functions were observed.
20例良性前列腺增生患者接受抗雄激素药物醋酸氯地孕酮（Prostal）治疗，每日50毫克，持续3个月。作为对照，20例前列腺增生患者接受前列康治疗，这是一种由植物提取物组成的非激素药物，每日6片，疗程相同。前列康组14例患者（70%）和醋酸氯地孕酮组18例患者（90%）的主观症状有显著改善。虽然经直肠超声断层扫描测量，前列康组患者3个月后前列腺大小和重量无显著变化，但醋酸氯地孕酮组11例患者（55%）3个月后前列腺大小和重量明显减轻。4例患者在醋酸氯地孕酮治疗期间抱怨出现阳痿，但未观察到对肝和/或肾功能的其他副作用。
